Boston Scientific (BSX) Stock on December 10, 2025: Why Shares Are Sliding While the Growth Story Stays Intact

Boston Scientific Corporation (NYSE: BSX) is having a rough early December on the stock market—even as its earnings, pipeline and analyst forecasts remain firmly bullish.

As of December 10, 2025, Boston Scientific stock is trading around $92.5 per share, roughly 15–16% below its 52‑week high of $109.50 set on September 9. The stock has logged seven straight down days, including a 1.4% drop to $92.53 on December 9, on unusually heavy volume of 12.7 million shares versus a 50‑day average of about 9.1 million. ^[1]

Yet over the past year, BSX still shows a small positive return and remains up strongly over five years, even after a three‑month slide of roughly 14–15%. ^[2]

So what’s really going on with Boston Scientific stock as of December 10, 2025—and what are analysts, models and recent news saying about its future?

1. Where Boston Scientific Stock Stands Today

Price & performance snapshot (as of Dec. 10, 2025)

Share price: about $92.5
52‑week range: roughly $86 – $110 ^[3]
Distance from 52‑week high: ~15.5% below the $109.50 peak. ^[4]
Recent momentum: 5‑day return about ‑5%, 1‑month about ‑7–8%, 3‑month about ‑14–15%. ^[5]
Longer‑term performance: still up low‑single digits over 12 months and around 170% over five years, according to MarketBeat total‑return data. ^[6]

Short term, the tape looks ugly: BSX has been slipping almost every day in early December while broad medtech sentiment cooled and investors reassessed high‑multiple growth names. But that pullback sits on top of years of outperformance, powered by structural growth in minimally invasive cardiovascular and electrophysiology procedures.

2. Fundamentals: Q3 2025 Earnings Were a Clear Beat

The recent share‑price weakness is not because the business is faltering. In fact, Q3 2025 results were very strong.

In its October 22 report for the quarter ended September 30, 2025, Boston Scientific delivered: ^[7]

Net sales of $5.065 billion,
- +20.3% year over year (reported),
- +19.4% operational,
- +15.3% organic—above the company’s own 12–14% organic growth guidance.
Adjusted EPS of $0.75, beating the company’s $0.70–0.72 guidance and topping the $0.71 consensus forecast. ^[8]
GAAP EPS of $0.51 per share. ^[9]

Segment and geographic growth were equally impressive: ^[10]

Cardiovascular segment:
- Net sales +22.4% reported, +21.5% operational, +19.4% organic.
MedSurg segment:
- Net sales +16.4% reported, +15.6% operational, +7.6% organic.
By region:
- United States: +27.0% reported/operational.
- APAC: +17.1% reported.
- LACA: +10.4% reported.
- EMEA: modest +2.6% reported, with some FX and product mix headwinds.

On the Q3 update, management again raised full‑year 2025 guidance: ^[11]

2025 net sales growth: about +20% reported and +15.5% organic versus 2024.
Full‑year adjusted EPS:$3.02–$3.04, implying ~20–21% EPS growth.
Q4 2025 guidance:
- Organic net sales growth 11–13%,
- Adjusted EPS $0.77–$0.79.

For context, 2024 net sales were around $16.7 billion, so guidance implies 2025 revenue in the $20 billion neighborhood—consistent with external sell‑side forecasts. ^[12]

In other words: fundamentals are accelerating even as the share price has been sliding.

3. Growth Engines: Farapulse, Farapoint, Watchman and Beyond

Boston Scientific’s premium valuation is built on a set of fast‑growing franchises, particularly in structural heart, electrophysiology and stroke prevention.

Pulsed Field Ablation (PFA): Farapulse + Farapoint

Boston Scientific is one of the leaders in pulsed field ablation, a next‑generation technology to treat atrial fibrillation (AFib). Its FARAPULSE™ PFA System is already a key growth driver, and now the ecosystem is being expanded:

On November 27, 2025, the company received CE Mark in Europe for the FARAPOINT™ PFA catheter, designed to add focal precision to the Farapulse platform and create both focal and linear lesions in complex heart anatomies. ^[13]
Trade press coverage notes that the approval strengthens Boston Scientific’s competitive position in the PFA market against Medtronic, Johnson & Johnson and Abbott. ^[14]

Earlier in 2025, clinical data from the ADVANTAGE AF trial showed positive outcomes for the Farapulse/Farapoint combo, including effective ablation for typical atrial flutter, supporting the technology’s safety and efficacy. ^[15]

Analysts see PFA as a multi‑billion‑dollar opportunity:

An Investor’s Business Daily piece highlighted Farapulse as a major driver of electrophysiology sales, which surged in earlier quarters, and called potential U.S. approval of Farapoint an important near‑term catalyst for further adoption. ^[16]

Watchman left‑atrial appendage closure

The WATCHMAN™ FLX Pro left‑atrial appendage closure device remains another pillar:

Prior coverage from Investor’s Business Daily noted Watchman sales growing around the high‑20s to mid‑30s percent year on year, and projected combined 2025 sales for Watchman plus electrophysiology products of over $5.2 billion, potentially reaching $8.5+ billion by 2028. ^[17]

That concentration in scaled, high‑margin cardio procedures is a big part of why Boston Scientific is growing faster than many diversified medtech peers.

Neuromodulation and chronic pain: Nalu Medical

In September 2025, Boston Scientific announced a deal to acquire Nalu Medical, a company focused on minimally invasive peripheral nerve stimulation systems for chronic pain. Reuters reported that Boston Scientific agreed to pay about $533 million for the equity it does not already own, with additional milestone‑based payments, reinforcing its neuromodulation portfolio. ^[18]

Analysts see Nalu’s miniaturized, battery‑free nerve stimulation platform as complementary to Boston Scientific’s existing pain and neuromodulation offerings, potentially boosting growth and margins in that franchise over time. ^[19]

Renal denervation and hypertension: SoniVie

Earlier in 2025, Boston Scientific also moved decisively into renal denervation (RDN):

On March 3, 2025, the company announced an agreement to acquire SoniVie Ltd., developer of the TIVUS™ intravascular ultrasound system, an investigational RDN platform that uses ultrasound to denervate renal artery nerves in treatment‑resistant hypertension. ^[20]
The deal is valued at up to $540 million, with an upfront payment of about $360 million and up to $180 million tied to regulatory milestones. ^[21]

Renal denervation is a slowly emerging market, but it has gained regulatory traction in the U.S. since 2023 and is seen as a long‑term growth vector for companies with differentiated technology. ^[22]

4. Fresh December 2025 Headlines Driving the Story

Several very recent developments—most within the last two weeks—are particularly relevant for Boston Scientific’s stock narrative as of December 10, 2025.

4.1. New insurance coverage for the Intracept™ back‑pain procedure

On December 10, Becker’s Spine Review reported that Health Care Service Corporation (HCSC), one of the largest U.S. commercial insurers, has granted coverage for Boston Scientific’s Intracept™ procedure for chronic vertebrogenic low back pain. ^[23]

Key points:

HCSC’s coverage took effect December 1, 2025,
The policy covers more than 26 million people, significantly expanding the addressable U.S. patient pool. ^[24]
Intracept is a one‑time, minimally invasive, implant‑free outpatient procedure that ablates the basivertebral nerve inside the vertebral body to relieve chronic low back pain. ^[25]

This new policy adds to a growing list of commercial and government payers covering Intracept, including recent TRICARE updates for 2026, and supports Boston Scientific’s pain management and interventional spine growth thesis. ^[26]

4.2. New $189 million facility in Minnesota

MassDevice recently reported that Boston Scientific has purchased a new facility in Maple Grove, Minnesota, for nearly $189 million, further expanding its manufacturing and operations footprint in a major medtech hub. ^[27]

While details on incremental capacity and product lines have not been fully disclosed, such a large real‑estate investment underscores the company’s expectation of continued volume growth across its portfolio.

4.3. European approval for the FARAPOINT PFA catheter

As noted above, at the end of November Boston Scientific obtained CE mark for the FARAPOINT focal PFA catheter, rounding out its pulsed‑field toolkit in Europe. ^[28]

This approval aligns with strong clinical data and supports the company’s goal of leading the global PFA market, a segment that most analysts expect to grow rapidly as ablation procedures shift away from traditional thermal energy. ^[29]

5. What Wall Street Is Saying: Ratings, Targets and Forecasts

5.1. Consensus rating: “Buy” / “Strong Buy”

Across the Street, Boston Scientific is still very much a favorite in medtech:

MarketBeat: 25 analysts over the last 12 months; 23 “Buy”, 2 “Hold,” 0 “Sell.” Consensus rating: “Buy”, very close to “Strong Buy.” ^[30]
StocksGuide: among 40 analysts, 37 rate BSX as “Buy” and 3 as “Hold,” with no sells. ^[31]
StockAnalysis and other platforms classify BSX as a “Strong Buy” based on the proportion of buy ratings. ^[32]

In short, the Street is overwhelmingly bullish on the name despite the current drawdown.

5.2. Price targets: 30–40% upside vs. today’s price

Analysts’ 12‑month targets cluster well above the current ~$92 handle:

MarketBeat: Average target $123.77, with a high of $140 and a low of $108—implying about 33.6% upside from roughly $92.65. ^[33]
StocksGuide: Average target around $129.54, based on 36 estimates, implying ~40% upside from a price of $92.53. High target $147, low $102.47. ^[34]
Other aggregators (e.g., StockAnalysis, TipRanks) generally show average targets in the $124–$126 range, with most major brokers rating BSX “Buy” or “Outperform.” ^[35]

Notable individual calls:

Bank of America Securities analyst Travis Steed recently reiterated a “Buy” rating with a $120 price target, citing strong growth potential in electrophysiology and the PFA market. ^[36]
RBC Capital has reiterated an “Outperform” rating with a $125 target, pointing to strong financial performance and a robust pipeline. ^[37]

5.3. Earnings and revenue forecasts

Sell‑side models see Boston Scientific continuing its high‑teens to low‑20s growth trajectory:

Analysts compiled by StocksGuide expect 2025 revenue of about $20.3 billion, up roughly 21% from 2024, and 2026 revenue of about $22.6 billion (+11%). ^[38]
Consensus EPS for 2025 is around $3.07, roughly 65% higher than 2024 EPS, with mid‑teens EPS growth projected out to 2030. ^[39]
A detailed “bull case” thesis summarized by InsiderMonkey emphasizes potential for 8–10% annual revenue growth, margin expansion and double‑digit EPS CAGR, driven by cardiology, electrophysiology and minimally invasive therapies. ^[40]

Many models also assume gradual margin expansion, with EBITDA margin rising from roughly 23% in 2024 to 30%+ over the next several years as scale, mix shift and manufacturing efficiencies kick in. ^[41]

6. Valuation: Premium Multiple, Mixed Narrative

Here’s where things get more nuanced.

6.1. High P/E and EV/EBITDA multiples

At around $92–93, BSX trades at:

A trailing P/E ratio near 49–50x, according to multiple sources including Public.com, Simply Wall St and StocksGuide. ^[42]
An EV/EBITDA multiple of roughly 31–34x, significantly above its own historical average and above many large medtech peers. ^[43]

Simply Wall St’s valuation work is a good snapshot of the current debate: ^[44]

Their model estimates a fair value of about $126.48 per share—about 26% above a recent close around $93.84.
At the same time, they point out that BSX’s current P/E of ~49.8x is well above peers at ~40x and above what they view as a “fair” P/E around 38x, arguing that the margin for error is limited if growth slows.

6.2. Is the pullback a valuation opportunity?

Given the combination of premium multiples and rapid earnings growth, different frameworks can lead to different conclusions:

Bullish view: Discounted‑cash‑flow and long‑term growth narratives (e.g., InsiderMonkey, Simply Wall St) see the current pullback as the market temporarily mispricing a company that can grow revenue high single digits to low double digits for many years while expanding margins, justifying today’s high multiple. ^[45]
Cautious view: Other commentary—like the “Has Boston Scientific’s Strong Runway in Minimally Invasive Therapies Stretched Its Valuation?” note on Yahoo Finance—raises concerns that even a fantastic story can be over‑discounted if growth expectations are already priced in. ^[46]

A fair summary: compared with more diversified medtech peers, Boston Scientific trades rich but not absurd—and the current drawdown has pulled valuation down meaningfully from 2024’s peaks.

7. Technicals and Sentiment: Short‑Term Pressure

From a technical and sentiment standpoint, BSX is clearly under some pressure in early December:

MarketWatch highlighted that December 9’s close marked seven straight daily declines, with the stock lagging key competitors like Abbott, Stryker and Medtronic and trading about 15.5% below its September high. ^[47]
Data compiled by MarketBeat show 5‑day returns around ‑5% and 3‑month returns around ‑14–15%, even though the stock remains modestly positive YTD. ^[48]
A technical screen from Intellectia.ai recently characterized Boston Scientific’s moving‑average profile as “leaning bearish”, with more negative than positive signals in the short term. ^[49]
Morpher’s AI‑driven analysis flagged a bearish short‑term signal on December 8, 2025, noting negative sentiment in medtech after an FDA panel voted against a Johnson & Johnson heart‑failure shunt, and increased investor focus on other device players such as Zimmer Biomet. ^[50]

In other words, the stock’s recent weakness appears driven more by sentiment, sector rotation and regulatory nerves than by any deterioration in Boston Scientific’s own numbers.

8. Key Risks to the BSX Investment Story

Even the most bullish long‑term views acknowledge several important risks:

Regulatory and clinical risk
- Boston Scientific’s growth engines—PFA, structural heart, neuromodulation, renal denervation—are highly regulated, and any negative clinical data, safety signal or FDA/EMA decision could hit growth or trigger recalls.
Reimbursement and pricing pressure
- While news like the HCSC Intracept coverage is clearly positive, coverage decisions can also go the other way, especially as payers scrutinize high‑cost procedures and medtech pricing. ^[51]
Competition
- In virtually every major category—PFA, stents, structural heart, neuromodulation—Boston Scientific faces heavy competition from Medtronic, Abbott, Johnson & Johnson and emerging players, which could pressure pricing or slow share gains. ^[52]
Integration and execution risk
- Ongoing acquisitions like Nalu Medical and SoniVie must be integrated successfully, with realized synergies and no major operational disruptions. ^[53]
Valuation risk
- With a P/E near 50x and EV/EBITDA above 30x, a change in interest‑rate expectations, sector sentiment or growth trajectory could compress multiples and hurt returns even if earnings keep growing. ^[54]

9. Bottom Line: Strong Story, Weak Tape

Putting everything together as of December 10, 2025:

The business:
- Double‑digit organic growth, Q3 beat on revenue and EPS, raised 2025 guidance, strong momentum in cardiovascular, EP and structural heart. ^[55]
The pipeline & strategy:
- CE mark for FARAPOINT, growing Farapulse platform, expanding Intracept coverage, entry into renal denervation, neuromodulation strengthened by Nalu, plus continued investment in capacity like the new Minnesota facility. ^[56]
The Street view:
- Overwhelming “Buy” consensus, average targets 30–40% above today’s price, and long‑term models pointing to sustained revenue and EPS growth. ^[57]
The stock:
- Near‑term technical downtrend after a multi‑session slide, rich—but easing—valuation multiples, and heightened sensitivity to sector sentiment and macro risk. ^[58]

For investors tracking Boston Scientific, the question after this December pullback is less about whether the underlying story is intact—it clearly is—and more about what price you’re willing to pay for that growth and how much volatility you can tolerate along the way.

References

Eli Lilly (LLY) After Hours: How a $6 Billion Bet, Fresh Oncology Data and Fed Rate Cut Set the Stage for December 11, 2025

Intel Stock After Hours on December 10, 2025: EU Fine Cut, Russia Lawsuits and AI Strategy – What to Watch Before the December 11 Open

BitMine Immersion Technologies (BMNR) After-Hours: Ethereum Treasury Stock Hovers Near $40 – What to Know Before the December 11, 2025 Open

Robinhood (HOOD) After the Bell on December 10, 2025: November Metrics, Valuation Jitters and What to Watch Before the December 11 Open

Carvana (CVNA) Stock After Hours on December 10, 2025: S&P 500 Buzz, 12‑Day Rally and What to Watch Before the December 11 Open